72 results about "Quetiapine Fumarate" patented technology

The invention provides a quetiapine fumarate tablet which comprises active ingredient quetiapine fumarate or pharmaceutically acceptable salt, and at least one pharmaceutic adjuvant; the quetiapine fumarate tablet also comprises one or more specific acids which can promote a medicine to be rapidly dissolved out; and fumaric acid is preferentially selected. The invention also relates to a preparation method of the quetiapine fumarate tablets. By the invention, the product which can be rapidly dissolved out and has good stability can be acquired, and the quality of the product can be improved.

The invention relates to a preparation method of pure quetiapine fumarate and the steps of the process thereof are that: (1)chlorination: four materials of dibenzo(b,f)(1,4)thiazepine-11-(10H)-ketone, chlorinated oxidant, N,N-Dimethylaniline and toluol react to obtain toluol solution of chloride; (2) addition and salification: the toluol solution of chloride reacts to obtain quetiapine according to the ratio of 1:0.5-1:0.5-0.8 of cyclic product (kg) to N-(2-(2-Hydroxyethoxy)ethyl)piperazine (kg) to anhydrous sodium carbonate; the mixture of the quetiapine (kg) and fumaric acid (kg) and ethanol (kg) is then salified to obtain the quetiapine fumarate according to the respective ratio 1:0.1-0.3:2-4. The invention effectively controls the impurity content of the quetiapine fumarate below 0.1 percent, improves the quality of products and achieves the standard of pharmaceutical purity and causes little side effects to patients. In addition, the invention also solves the problems of recovery of phosphorus oxychloride and environment pollution, shortens the cycle of reaction, improves the yield and reduces the cost.

The invention relates to a quetiapine fumarate tablet and a preparation method thereof. The tablet of the invention comprises quetiapine fumarate, a filler, a disintegrant, povidone and magnesium stearate in certain proportions. The preparation method comprises the following steps: granulating the quetiapine fumarate, the filler and the disintegrant by a wet method; then adding the povidone and granulating into a soft material; screening, drying and finishing the soft material; adding the magnesium stearate and mixing; measuring the content and calculating the tablet weight; and respectively tabletting and coating to obtain the quetiapine fumarate tablet. The tablet can be used for treating schizophrenia. By using the formula provided by the invention, the defect of poor particle mobility during granulating in the prior art is overcome.

The invention discloses a preparation process of a quetiapine fumarate slow release tablet, belonging to the technical field of preparing medicinal slow / controlled-release preparations. In the process, a soluble slow-release accessory is used as a retarding agent, and slow-release particles are prepared by using a fusion-method solid dispersion technology and are tabletted. The quetiapine fumarate slow release tablet is the slow-release matrix tablet prepared by using a process of externally covering the tablet with a quick-release thin-film coating. The quetiapine fumarate in the invention has the in-vitro release characteristics as follows: after 750ml of 0.1NHCl is added for 2 hours, the release amount of quetiapine fumarate within 0-2 hours is 0-35%, and after 250ml of K3PO4 is added, the release amounts of the quetiapine fumarate within 2-8 hours, 8-12 hours and 12-20 hours are respectively 35-60%, 60-80% and 80-100%. The process has the advantages of simple and safe flow, controllable quality, low cost, short production period and great suitability for large-scale industrial production.

A pharmaceutical composition comprising (i) quetiapine or a pharmaceutically acceptable salt thereof, especially quetiapine fumarate; (ii) a mixed excipient comprising an intimate admixture of polyvinylacetate and polyvinylpyrrolidone in a weight ratio from 5:2 to 10:2; and, optionally (iii) an acid especially fumaric acid.

A pharmaceutical composition comprising (i) quetiapine or a pharmaceutically acceptable salt thereof, especially quetiapine fumarate; (ii) a mixed excipient comprising an intimate admixture of polyvinylacetate and polyvinylpyrrolidone in a weight ratio from 5:2 to 10:2; and, optionally (iii) an acid especially fumaric acid.

The invention provides a solid quetiapine fumarate liposome preparation and a preparation method thereof. According to the preparation method, quetiapine fumarate, yolk lecithin, cholesterol, soyasterol and sorbitam stearate are selected according to a specific weight ratio and prepared into high-quality quetiapine fumarate liposome, and the quetiapine fumarate liposome is prepared into a solid preparation according to a common preparation method. Compared with the traditional preparation, the preparation provided by the invention has the advantages of greatly improved stability, bioavailability and quality and reduced toxic and side effects.

A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

The invention discloses a quetiapine fumarate oral preparation and a preparation method thereof. The quetiapine fumarate oral preparation is mainly prepared by raw materials with the following proportion by weight: 25-300 parts of quetiapine fumarate counted by quetiapine, 2-100 parts of disintegrating agent and 5-400 parts of filling agent. The preparation method of the oral preparation comprises the following process steps: (1) the quetiapine fumarate is taken, smashed, screened and evenly mixed with flavoring agent and the disintegrating agent, and wetting agent is added for preparing soft materials; (2) the soft materials are screen through a 20-mesh sieve for carrying out the granulation and the drying, the 20-mesh sieve is used for carrying out the size stabilization, the filling agent, an odor correcting agent, glidant and lubricant are added for even mixing; (3) the content of the drug which is evenly mixed is measured, the tablet weight is calculated, and the tablet pressing is carried out for the preparation. The oral preparation can be rapidly disintegrated in oral cavity without the use of water for the drug administration; the absorption is rapid and the bioavailability is high; and the taste is good.

The present invention relates to a novel polymorph of Quetiapine fumarate and a simple method for its preparation.

The invention discloses a quetiapine synthesizing method. O-chlorobenzoic acid with the low price is adopted as a starting material to react with thiophenol, and then ring closure is performed to obtain thioxanthone. Hydroxyl amination and Beckmann rearrangement are performed to obtain a key intermediate dibenzo[b,f][1,4]thiazepines-11-(10H)one, chlorination is performed, then, a reaction is performed on 1-(2-hydroxyethoxy)ethylpiperazine with the existence of acid-binding agent to obtain quetiapine, and the quetiapine and fumaric acid form a salt in an absolute ethyl alcohol system to obtain a product. According to the quetiapine synthesizing method, raw materials are low in price and easy to obtain, the steps are simple, operation is easy, and the cost can be effectively lowered. According to the method, the high-purity quetiapine can be obtained, the liquid phase purity of the obtained semi-fumaric acid quetiapine obtained through salt forming is 99% or above, and the quetiapine synthesizing method can be applied to the field of medicine.

The invention provides a solid quetiapine fumarate liposome preparation and a preparation method thereof. According to the preparation method, quetiapine fumarate, yolk lecithin, cholesterol, soyasterol and sorbitam stearate are selected according to a specific weight ratio and prepared into high-quality quetiapine fumarate liposome, and the quetiapine fumarate liposome is prepared into a solid preparation according to a common preparation method. Compared with the traditional preparation, the preparation provided by the invention has the advantages of greatly improved stability, bioavailability and quality and reduced toxic and side effects.

The invention relates to a quetiapine fumarate film-controlled slow-release pellet capsule. A slow-release film of the quetiapine fumarate film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the quetiapine fumarate film-controlled slow-release pellet contains low-substituted hydroxypropyl cellulose having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of the low-substituted hydroxypropyl cellulose. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 19 to 35%. The quetiapine fumarate film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxypropyl cellulose having high water expansibility and thus after absorbing water, the quetiapine fumarate film-controlled slow-release pellet expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the quetiapine fumarate film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention provides a sustained-release tablet containing quetiapine fumarate. The sustained-release tablet comprises the following components according to weight percent: 12.5% to 60% of the quetiapine fumarate according to quetiapine, 10% to 40% of sustained-release material and other pharmaceutic adjuvants as the rest, wherein the sustained-release material is a composition of carbomer and hydroxyethyl cellulose. After being dosed, the sustained-release tablet can slowly and continuously release as required, so as to maintain the effective treatment concentration, thereby achieving a long-acting effect by dosing once a day. Additionally, according to the sustained-release tablet, a dry granulation tableting process is adopted, the preparation process is simple, large-scale industrial production is facilitated, and the production cost can be effectively reduced.